Rituxan RA Approval Raises The Stakes, But With A Lower Price
Executive Summary
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)
You may also be interested in...
Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules
Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein
Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules
Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said